Turnstone Biologics
TSBX
TSBX was delisted on the 8th of August, 2025.
1 hedge funds and large institutions have $0 invested in Turnstone Biologics in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 22 closing their positions.
36.28% less ownership
Funds ownership: 36.45% → 0.17% (-36%)
96% less funds holding
Funds holding: 23 → 1 (-22)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $3.03M → $0 (-$3.03M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$937 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.11M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$407K |
| 3 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$396K |
| 4 |
TPC
Takeda Pharmaceutical Company
Tokyo,
Japan
|
-$322K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$293K |
TSBX Hedge Fund Activity: Q3 2025 in Review
1 of the 7,643 institutional investors tracked by Wall St. Rank reported a position in Turnstone Biologics (TSBX) for Q3 2025, worth a combined $0 — down 100% from $3.03M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of TSBX and 0 opened new positions — a net loss of 22 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was XTX Topco, adding an estimated $937. The largest seller was OrbiMed, exiting entirely with an estimated $1.11M sold.
- 1 institutional investor held Turnstone Biologics (TSBX) as of Q3 2025, down from 23 in Q2 2025.
- Funds reported $0 of Turnstone Biologics stock for Q3 2025, down 100% quarter-over-quarter.
- 0 funds opened new Turnstone Biologics positions in Q3 2025 and 22 closed out, a net change of -22 holders.
- The largest Turnstone Biologics buyer in Q3 2025 was XTX Topco, an estimated $937 added.
- The largest Turnstone Biologics seller in Q3 2025 was OrbiMed, an estimated $1.11M sold.
Based on aggregated 13F filings for Q3 2025.